CoreRx has added an Xcelodose precision powder micro-dosing system to its product development capabilities for preclinical and early phase clinical GMP supply. According to the company, the Xcelodose decreases processing time and API use, generating significant cost savings to clients. “CoreRx is continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times,” said Mark Licarde, CoreRx’s vice president of m...